Ubix Therapeutics Inc. develops novel anti-cancer drugs based on Degraducer® platform technology.

Degraducer® is a powerful next generation inhibitor technology that enables targeting of disease-related targets that were previously undruggable.

We create novel cancer immunotherapy based on thorough understanding of the human immune system and target proteins. By doing so, we hope to contribute to increased life span and improved quality of life.